22 §8737. Rulemaking
§8737. Rulemaking The organization may adopt rules to implement this subchapter. Rules adopted pursuant to this section are major substantive rules as defined in Title 5, chapter 375, subchapter 2‑A. [PL 2019, c. 470, §8 (NEW).] SECTION HISTORY PL 2019, c. 470, §8 (NEW).
22 §8741. International referenced rate pricing
§8741. International referenced rate pricing 1. Definitions. As used in this section, unless the context otherwise indicates, the following terms have the following meanings. A. “Manufacturer” has the same meaning as in section 8731, subsection 3. [PL 2021, c. 606, §1 (NEW).] B. “Prescription drug” has the same meaning as in section 8731, […]
22 §8716. Health care improvement studies (WHOLE SECTION TEXT EFFECTIVE ON CONTINGENCY: See PL 2013, c. 528, §12)
§8716. Health care improvement studies (CONTAINS TEXT WITH VARYING EFFECTIVE DATES) (WHOLE SECTION TEXT EFFECTIVE ON CONTINGENCY: See PL 2013, c. 528, §12) The board may approve the disclosure of protected health information to persons conducting health care improvement studies, subject to the following conditions. [PL 2013, c. 528, §10 (NEW); PL 2013, c. […]
22 §8717. Covered entities’ access to protected health information (WHOLE SECTION TEXT EFFECTIVE ON CONTINGENCY: See PL 2013, c. 528, §12)
§8717. Covered entities’ access to protected health information (CONTAINS TEXT WITH VARYING EFFECTIVE DATES) (WHOLE SECTION TEXT EFFECTIVE ON CONTINGENCY: See PL 2013, c. 528, §12) 1. Permitted uses and disclosures; definitions. The organization may disclose protected health information without authorization by the subject of the information for the treatment activities of any health care […]
22 §8718. Maine Health Data Organization Health Information Advisory Committee
§8718. Maine Health Data Organization Health Information Advisory Committee The Maine Health Data Organization Health Information Advisory Committee, referred to in this section as “the advisory committee,” is established in accordance with this section to make recommendations to the organization regarding public reporting of health care trends developed from data reported to the organization pursuant […]
22 §8719. Provider database and service locator tool
§8719. Provider database and service locator tool 1. Provider database. The organization shall develop and maintain a multipayor provider database that must be used by the department to provide information for a service locator available on a publicly accessible website for use by the public, by providers and by state agencies in accordance with this […]
22 §8731. Definitions
§8731. Definitions As used in this subchapter, unless the context otherwise indicates, the following terms have the following meanings. [PL 2019, c. 470, §8 (NEW).] 1. Brand-name drug. “Brand-name drug” means a prescription drug marketed under a proprietary name or registered trademark name, including a biological product. [PL 2019, c. 470, §8 (NEW).] […]
22 §8732. Drug price notifications and disclosures
§8732. Drug price notifications and disclosures 1. Notifications by manufacturers. [PL 2021, c. 305, §4 (AMD); MRSA T. 22 §8732, sub-§1 (RP).] 1-A. Public notice of substantial drug price change or introduction. No later than January 30, 2022 and annually thereafter, the organization shall produce and post on its publicly accessible website a list of […]
22 §8708. Clinical data
§8708. Clinical data Clinical data must be filed, stored and managed as follows. [PL 1995, c. 653, Pt. A, §2 (NEW); PL 1995, c. 653, Pt. A, §7 (AFF).] 1. Information required. Pursuant to rules adopted by the board for form, medium, content and time for filing, each health care facility shall file with […]
22 §8733. Confidentiality
§8733. Confidentiality Information provided to the organization as required by this subchapter by a manufacturer, wholesale drug distributor or pharmacy benefits manager is confidential and not a public record under Title 1, chapter 13, except that the organization may share information: [PL 2019, c. 470, §8 (NEW).] 1. Bureau of Insurance. With the Department […]